Rebecca Mae Allen MD MPH
Neuropsychiatry
Partner, Director of Research & Neuropsychiatry, Seattle Neuropsychiatric Treatment Center
Join to View Full Profile
805 Madison StSte 401Seattle, WA 98104
Phone+1 206-467-6300
Dr. Allen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Rebecca Allen is a psychiatrist in Seattle, WA. She received her medical degree from Oregon Health & Science University School of Medicine. She attended residency at Harvard Longwood and fellowship training at Brigham & Women's Hospital. She specializes in neuropsychiatry.
Education & Training
Beth Israel Deaconess Medical CenterChief Residency, Psychiatry, 2014 - 2015- Beth Israel Deaconess Medical CenterResidency, Psychiatry, 2011 - 2015
Mass General Brigham/Brigham and Women's Hospital/Harvard Medical SchoolResidency, Psychiatry, 2011 - 2015
Oregon Health and Science University School of MedicineClass of 2011
Certifications & Licensure
WA State Medical License 2017 - 2026
ID State Medical License 2021 - 2025
MT State Medical License 2021 - 2025
MA State Medical License 2015 - 2018
American Board of Psychiatry and Neurology Psychiatry
UCNSBehavioral Neurology and Neuropsychiatry
Awards, Honors, & Recognition
- Clinical TMS Society Service Award Clinical TMS Society, 2021
Clinical Trials
- A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression Start of enrollment: 2019 Sep 26
- Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD Start of enrollment: 2023 Feb 14
- Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for MDD Start of enrollment: 2023 Aug 17
Publications & Presentations
PubMed
- Suicide characteristics in patients with marked treatment-resistant major depressive disorder: A RECOVER trial report.Victoria C de Leon, Rebecca M Allen, João Quevedo, Patricio Riva-Posse, Scott T Aaronson
Journal of Affective Disorders. 2025-04-01 - 3 citationsEffects of vagus nerve stimulation on daily function and quality of life in markedly treatment-resistant major depression: Findings from a one-year, randomized, sham-c...A John Rush, Charles R Conway, Scott T Aaronson, Mark S George, Patricio Riva-Posse
Brain Stimulation. 2024-12-18 - 3 citationsVagus nerve stimulation in treatment-resistant depression: A one-year, randomized, sham-controlled trial.Charles R Conway, Scott T Aaronson, Harold A Sackeim, Mark S George, John Zajecka
Brain Stimulation. 2024-12-18
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
